Physician profile
Mitchell James Maccready
NPI 1821593104
$6,326.93
in general payments reported to CMS, 2019-2025
36 companies · $153 in 2025
The $153 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $623 · 2022: $2,275 · 2023: $1,379 · 2024: $1,897 · 2025: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,429.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,428.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $978.58 | 2021-2024 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $852.44 | 2021-2024 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $528.15 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $525.72 | 2021-2024 | Jardiance, Ofev |
| Lilly USA, LLC | $499.73 | 2021-2024 | Mounjaro, Jardiance, Emgality |
| Abbvie INC. | $390.17 | 2021-2024 | |
| Lundbeck LLC | $345.27 | 2022-2025 | Rexulti |
| Mylan Specialty L.P. | $234.45 | 2021-2024 | Yupelri |
| Otsuka America Pharmaceutical, INC. | $211.75 | 2021-2024 | Rexulti, Abilify Maintena |
| Sumitomo Pharma America, INC. | $196.23 | 2023-2025 | Gemtesa |
| Pfizer INC. | $165.94 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $140.65 | 2021-2024 | Eliquis |
| Biohaven Pharmaceutical Holding Company Ltd. | $116.63 | 2022 | |
| Axsome Therapeutics, INC. | $108.03 | 2022-2024 | Auvelity |
| Sunovion Pharmaceuticals INC. | $102.96 | 2022 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Maccready listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.